Heidelberg Pharma AG, a biotechnology company operating within the healthcare sector, continues its focus on the development and commercialization of novel cancer therapies. Based in Germany, the company conducts specialized research in pharmacology, drug metabolism, pharmacokinetics analysis, and molecular biology, specifically targeting oncology and inflammatory diseases.

The company serves patients and healthcare professionals within the German market. Heidelberg Pharma AG has been publicly traded since its initial public offering (IPO) on November 13, 2006. Its shares are listed on the Xetra stock exchange.

As of the market close on November 12, 2026, the company’s stock price was 2.09 EUR. Over the preceding 52-week period, the stock reached a high of 3.34 EUR on January 8, 2026, and a low of 1.98 EUR on October 22, 2026. The company maintains a market capitalization of 97,780,000 EUR and reports a price-to-earnings (P/E) ratio of -3.12.